A low molecular weight dextran sulphate, ILB®, for the treatment of amyotrophic lateral sclerosis (ALS): An open-label, single-arm, single-centre, phase II trial

Venkataramanan Srinivasan, Victoria Homer, Darren Barton, Abigail Clutterbuck-James, Siân Jenkins, Claire Potter, Kristian Brock, Ann Logan, Donna Smith, Lars Bruce, Zsuzsanna Nagy, Simon P. Bach

Open source

DOI
10.1371/journal.pone.0291285
Published
2024-07-11
Container
PLOS ONE
Publisher
Public Library of Science (PLoS)
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1371/journal.pone.0291285,
  title = {A low molecular weight dextran sulphate, ILB®, for the treatment of amyotrophic lateral sclerosis (ALS): An open-label, single-arm, single-centre, phase II trial},
  author = {Venkataramanan Srinivasan and Victoria Homer and Darren Barton and Abigail Clutterbuck-James and Siân Jenkins and Claire Potter and Kristian Brock and Ann Logan and Donna Smith and Lars Bruce and Zsuzsanna Nagy and Simon P. Bach},
  year = {2024},
  journal = {PLOS ONE},
  doi = {10.1371/journal.pone.0291285},
  url = {https://doi.org/10.1371/journal.pone.0291285}
}

RIS

TY  - JOUR
TI  - A low molecular weight dextran sulphate, ILB®, for the treatment of amyotrophic lateral sclerosis (ALS): An open-label, single-arm, single-centre, phase II trial
AU  - Venkataramanan Srinivasan
AU  - Victoria Homer
AU  - Darren Barton
AU  - Abigail Clutterbuck-James
AU  - Siân Jenkins
AU  - Claire Potter
AU  - Kristian Brock
AU  - Ann Logan
AU  - Donna Smith
AU  - Lars Bruce
AU  - Zsuzsanna Nagy
AU  - Simon P. Bach
PY  - 2024
JO  - PLOS ONE
DO  - 10.1371/journal.pone.0291285
UR  - https://doi.org/10.1371/journal.pone.0291285
ER  - 

APA

Srinivasan, V., Homer, V., Barton, D., Clutterbuck-James, A., Jenkins, S., Potter, C., Brock, K., Logan, A., Smith, D., Bruce, L., Nagy, Z., & Bach, S. P. (2024). A low molecular weight dextran sulphate, ILB®, for the treatment of amyotrophic lateral sclerosis (ALS): An open-label, single-arm, single-centre, phase II trial. PLOS ONE. https://doi.org/10.1371/journal.pone.0291285

Source records